IL-5 — Drug Target

All drugs that target IL-5 — marketed and clinical-stage. Includes 2 drug classes acting on this target.

Drug classes

IL-5 inhibitor · Anti-IL-5 monoclonal antibody

Marketed (1)

• EXDENSUR · GLAXOSMITHKLINE LLC · Other
  Depemokimab-ulaa binds to IL-5, blocking its interaction with the IL-5 receptor and reducing eosinophil activity.

Phase 3 pipeline (2)

• Placebo matching mepolizumab · GlaxoSmithKline · IL-5 inhibitor · Immunology
  Mepolizumab is an IL-5 inhibitor, which works by binding to the IL-5 protein and preventing it from interacting with its receptor on the surface of eosinophils, thereby reducing eosinophilic inflammation.
• Placebo to Mepolizumab · AstraZeneca · IL-5 inhibitor · Immunology
  Mepolizumab is an interleukin-5 (IL-5) inhibitor that blocks the action of IL-5, a cytokine involved in the production and survival of eosinophils.

Phase 2 pipeline (1)

• Mepolizumab 250 · GlaxoSmithKline · Anti-IL-5 monoclonal antibody · Immunology
  Interleukin-5 antagonist